Logo image of OGEN

ORAGENICS INC (OGEN) Stock Fundamental Analysis

NYSEARCA:OGEN - US6840235005 - Common Stock

1.03 USD
-0.09 (-7.9%)
Last: 8/29/2025, 8:04:00 PM
1.04 USD
+0.01 (+0.97%)
After Hours: 8/29/2025, 8:04:00 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to OGEN. OGEN was compared to 542 industry peers in the Biotechnology industry. Both the profitability and financial health of OGEN have multiple concerns. OGEN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OGEN had negative earnings in the past year.
OGEN had a negative operating cash flow in the past year.
OGEN had negative earnings in each of the past 5 years.
In the past 5 years OGEN always reported negative operating cash flow.
OGEN Yearly Net Income VS EBIT VS OCF VS FCFOGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

With a Return On Assets value of -717.68%, OGEN is not doing good in the industry: 97.60% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -717.68%
ROE N/A
ROIC N/A
ROA(3y)-410.14%
ROA(5y)-285.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OGEN Yearly ROA, ROE, ROICOGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K 4K -4K -6K

1.3 Margins

OGEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OGEN Yearly Profit, Operating, Gross MarginsOGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K -50K

More info and screens

0

2. Health

2.1 Basic Checks

OGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OGEN has more shares outstanding
OGEN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, OGEN has a worse debt to assets ratio.
OGEN Yearly Shares OutstandingOGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
OGEN Yearly Total Debt VS Total AssetsOGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -228.43, we must say that OGEN is in the distress zone and has some risk of bankruptcy.
OGEN has a worse Altman-Z score (-228.43) than 97.42% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -228.43
ROIC/WACCN/A
WACC9.57%
OGEN Yearly LT Debt VS Equity VS FCFOGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 0.87 indicates that OGEN may have some problems paying its short term obligations.
OGEN has a Current ratio of 0.87. This is amonst the worse of the industry: OGEN underperforms 88.75% of its industry peers.
OGEN has a Quick Ratio of 0.87. This is a bad value and indicates that OGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.87, OGEN is doing worse than 88.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.87
Quick Ratio 0.87
OGEN Yearly Current Assets VS Current LiabilitesOGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

OGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.49%, which is quite impressive.
Looking at the last year, OGEN shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)78.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.29%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, OGEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.02% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.67%
EPS Next 2Y40.35%
EPS Next 3Y25.6%
EPS Next 5Y15.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OGEN Yearly Revenue VS EstimatesOGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2021 2022 2023 200K 400K 600K 800K
OGEN Yearly EPS VS EstimatesOGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -200 -400 -600 -800 -1K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OGEN. In the last year negative earnings were reported.
Also next year OGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OGEN Price Earnings VS Forward Price EarningsOGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OGEN Per share dataOGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -10 -20 -30 -40 -50

4.3 Compensation for Growth

OGEN's earnings are expected to grow with 25.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.35%
EPS Next 3Y25.6%

More info and screens

0

5. Dividend

5.1 Amount

OGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORAGENICS INC

NYSEARCA:OGEN (8/29/2025, 8:04:00 PM)

After market: 1.04 +0.01 (+0.97%)

1.03

-0.09 (-7.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07
Earnings (Next)11-11 2025-11-11
Inst Owners1.32%
Inst Owner Change-61.5%
Ins Owners2.37%
Ins Owner Change-2.33%
Market Cap4.25M
Analysts82.86
Price Target2.04 (98.06%)
Short Float %6.79%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-93.33%
PT rev (3m)100%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)93.15%
EPS NY rev (3m)-105.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-56.05
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-2.08
FCFYN/A
OCF(TTM)-2.08
OCFYN/A
SpS0
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -717.68%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-410.14%
ROA(5y)-285.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.87
Quick Ratio 0.87
Altman-Z -228.43
F-Score2
WACC9.57%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.29%
EPS Next Y96.67%
EPS Next 2Y40.35%
EPS Next 3Y25.6%
EPS Next 5Y15.02%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y49.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.84%
EBIT Next 3Y-27.69%
EBIT Next 5YN/A
FCF growth 1Y-3.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.92%
OCF growth 3YN/A
OCF growth 5YN/A